Aldeyra Therapeutics (ALDX) Current Assets (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Current Assets for 14 consecutive years, with $47.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 43.97% year-over-year to $47.4 million; the trailing twelve-month figure through Jun 2026 stood at $47.4 million (down 43.97% YoY), and the FY2025 full-year result was $71.8 million, down 31.03% from the prior year.
• Current Assets retreated to $47.4 million in Q2 2026 per ALDX's latest filing, from $66.3 million in the prior quarter.
• Across five years, Current Assets topped out at $222.4 million in Q1 2022 and bottomed at $47.4 million in Q2 2026.
• Historically, Current Assets has averaged $130.0 million across 5 years, with a median of $133.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Current Assets soared 51.19% in 2022, then sank 43.97% in 2026.
• Over 5 years, Current Assets stood at $181.0 million in 2022, then dropped by 18.35% to $147.8 million in 2023, then retreated by 29.59% to $104.1 million in 2024, then plunged by 31.03% to $71.8 million in 2025, then slumped by 34.0% to $47.4 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $47.4 million, $66.3 million, and $71.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.